Trial Information

The Effect of Dulaglutide on Major Cardiovascular Events in Patients with Type 2 Diabetes: Researching Cardiovascular Events with a Weekly Incretin in Diabetes.

This study is for patients diagnosed with Type 2 Diabetes Mellitus who have vascular disease or cardiovascular risks. This trial is being conducted at 272 sites all around the world. It is an end-point trial and following Visit 4, there is an office visit every 3 months until a clinical end-point is reached. Subjects will receive a patient stipend between $45 and $70 for each completed visit.

Patient Inclusion Criteria:

Age 50 or older
Diagnosed with Type 2 Diabetes Mellitus
HbA1c ≤ 9.5%
Anti-hyperglycemic drug naive or treated with up to 2 oral hyperglycemic drugs with or without a glucagon-like peptide-1analog or basal insulin, or basal insulin alone
On stable hyperglycemic regimen for 3 months
Age equal to or greater than 50 years with established clinical vascular disease, or age equal to or greater than 55 years and subclinical vascular disease or age equal to or greater than 60 years and at least 2 or more cardiovascular risk factors

Patient Exclusion Criteria:

Uncontrolled diabetes
History of severe hypoglycemia in past year
Acute coronary or cerebrovascular event within past 2 months
History of pancreatitis, hepatic insufficiency , chronic renal failure or of C-cell thyroid disorder

Cheryl Nickles, Patient Recruitment Coordinator
Chase Medical Research, LLC
500 Chase Parkway, 3rd Floor
Waterbury, CT 06708
Phone: (203) 419-4404
Fax: (203) 465-7924
Email: cnickles@chasemr.com

View Map

Research Center Information: Chase Medical Research, LLC

If you would like to learn more about participating in this study, please send an email message using the form below.

Name:
Address:
City:
State:
Country:
Phone:
Email:
Message:

DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.